National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study
| dc.contributor.author | Jessica Price, Jessica Mooney, Carolyn Bain, John Tanko Bawa, Nikki Gurley, Amresh Kumar, Guwani Liyanage, Rouden Esau Mkisi, Chris Odero, Karim Seck, Evan Simpson, William P Hausdorff | |
| dc.date.accessioned | 2022-06-29T15:59:20Z | |
| dc.date.available | 2022-06-29T15:59:20Z | |
| dc.date.issued | 2022-01-21 | |
| dc.identifier.uri | https://repository.maseno.ac.ke/handle/123456789/5309 | |
| dc.description.abstract | Currently available live, oral rotavirus vaccines (LORVs) have significantly reduced severe rotavirus hospitalizations and deaths worldwide. However, LORVs are not as effective in low- and middle-income countries (LMIC) where rotavirus disease burden is highest. Next-generation rotavirus vaccine (NGRV) candidates in development may have a greater public health impact where they are needed most. The feasibility and acceptability of possible new rotavirus vaccines were explored as part of a larger public health value proposition for injectable NGRVs in LMICs. | en_US |
| dc.publisher | Elsevier | en_US |
| dc.subject | RotavirusRotavirus vaccines Next-generation rotavirus vaccines Value proposition New vaccine introduction Vaccine decision-making | en_US |
| dc.title | National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study | en_US |
| dc.type | Article | en_US |
Files in this item
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Trends of non-vaccination, under-vaccination and missed opportunities for vaccination (2003–2014) amongst children 0–23 months in Kenya
(Public Library of Science, 2024-02-06)Vaccines are effective and cost-effective. Non-vaccination, under-vaccination, and missed opportunities for vaccination (MOV), have contributed to incomplete vaccination coverage in Kenya. Analyzing their trends is essential ... -
Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
(Elsevier, 2015)Background The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antibodies associated with the prevention of Plasmodium falciparum infection. We assessed the association between anti-circumsporo ... -
Correction: Costs of continuing RTS, S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries
(Public Library of Science, 2021)Cost estimates under additional vaccine price assumptions are not included in the main result Table (Table 3). Please view S4 Table,“Unit cost of continuing to vaccinate in pilot areas at various vaccine prices,” for results ...